Albumin-Bound Paclitaxel: A Review of Its Use for the First-Line Combination Treatment of Metastatic Pancreatic Cancer-Reference-Cited by-同舟云学术

Albumin-Bound Paclitaxel: A Review of Its Use for the First-Line Combination Treatment of Metastatic Pancreatic Cancer

Published:2014-09-27 Issue:15 Volume:74 Page:1757-1768
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Hoy Sheridan M.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/content/pdf/10.1007/s40265-014-0291-8.pdf

Reference32 articles.

1. Seufferlein T, Bachet JB, Van Cutsem E, et al. Pancreatic adenocarcinoma: ESMO–ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii33–40.

2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: pancreatic adenocarcinoma (version 2.2014). 2014. http://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf . Accessed 8 Sep 2014.

3. Chiorean EG, Von Hoff DD. Taxanes: impact on pancreatic cancer. Anticancer Drugs. 2014;25(4):584–92.

4. Robinson DM, Keating GM. Albumin-bound paclitaxel: in metastatic breast cancer. Drugs. 2006;66(7):941–8.

5. Ma WW, Hidalgo M. The winning formulation: the development of paclitaxel in pancreatic cancer. Clin Cancer Res. 2013;19(20):5572–9.

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the therapeutic potential of diterpenes in gastric cancer: Mechanisms, efficacy, and clinical prospects;Biomolecules and Biomedicine;2024-08-15

2. Applications of human and bovine serum albumins in biomedical engineering: A review;International Journal of Biological Macromolecules;2023-12

3. Assessment of gemcitabine hydrochloride-based nanotherapeutics in cancer: a proof of concept study;Journal of Nanoparticle Research;2023-05-25

4. Liposomal co-delivery system encapsulating celastrol and paclitaxel displays highly enhanced efficiency and low toxicity against pancreatic cancer;Journal of Drug Delivery Science and Technology;2022-12

5. Emerging Nanotherapeutic Approaches to Overcome Drug Resistance in Cancers with Update on Clinical Trials;Pharmaceutics;2022-04-15